GlassScriptPhysician profile
Tiffany Wilburn
NPI 1346946373
$6,188.88
in general payments reported to CMS, 2019-2025
30 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,418 · 2024: $2,270 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,188.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $910.76 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $869.09 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $742.71 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $667.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $428.85 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $363.94 | 2023-2025 | Trintellix |
| Glaxosmithkline, LLC. | $290.09 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $270.45 | 2024-2025 | Xyosted |
| Lundbeck LLC | $199.70 | 2023-2025 | Vyepti, Rexulti |
| Amgen INC. | $171.03 | 2023-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $154.12 | 2023-2025 | Rexulti |
| Pfizer INC. | $142.88 | 2023-2025 | |
| Ardelyx, INC. | $113.87 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $112.86 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $112.51 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $111.86 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $79.83 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $66.05 | 2024-2025 | Keveyis |
| Halozyme INC | $53.18 | 2023 | |
| Indivior INC. | $52.24 | 2024-2025 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.26 | 2024-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $40.81 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Idorsia Pharmaceuticals US INC | $31.15 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $28.63 | 2025 | Austedo Xr |
| Sanofi Pasteur INC. | $28.54 | 2025 | |
| Tolmar, INC. | $22.70 | 2025 | Jatenzo |
| Sumitomo Pharma America, INC. | $20.94 | 2024 | Gemtesa |
| Dexcom, INC. | $20.00 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.86 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $15.99 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Wilburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.